MedTrace Logo

Desvenlafaxine for Preventive Treatment of Frequent Migraines

NCT07385755 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 440

Last updated 2026-02-04

No results posted yet for this study

Summary

To evaluate whether Desvenlafaxine can reduce the frequency and severity of migraine attacks in patients.

Conditions

Interventions

DRUG

Desvenlafaxine

Desvenlafaxine

DRUG

Placebo

placebo

Sponsors & Collaborators

  • Tongji Hospital

    lead OTHER

Principal Investigators

  • Wensheng Qu · Tongji Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-01
Primary Completion
2028-01-01
Completion
2028-01-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07385755 on ClinicalTrials.gov